Semax is a synthetic peptide widely studied in neuropharmacology research for its interaction with neurotrophic and cognitive-related signalling pathways. This article provides an educational overview of what the published scientific literature reports about Semax, its structure, and its mechanisms of interest. All information below is provided strictly for research and informational purposes.
What is Semax?
Semax is a synthetic heptapeptide (a chain of seven amino acids, sequence Met-Glu-His-Phe-Pro-Gly-Pro) derived from a fragment of the naturally occurring hormone ACTH (specifically the ACTH 4-10 region). Research literature notes that an added Pro-Gly-Pro tail on the end of the molecule makes it more resistant to enzymatic breakdown, and may carry pharmacological activity of its own. It was originally developed by researchers in Russia. It is typically supplied as a lyophilised powder for research use.
Mechanisms of interest
Scientific interest in Semax centres on its reported activity across several neurological pathways in research models. The published literature describes its study in relation to:
- BDNF and NGF — research describes Semax as being associated with increased expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), proteins studied in the context of neuronal growth and synaptic plasticity.
- TrkB receptor signalling — studies have examined its association with TrkB receptor activity, part of the BDNF signalling pathway.
- Neurotransmitter systems — research has looked at its influence on dopaminergic and serotonergic signalling.
- Neuroprotective and anti-inflammatory pathways — studies in experimental models, including stroke models, have explored its effects on neuronal survival and inflammatory signalling.
A frequently cited feature in the literature is that a single administration was associated with rapid, region-specific increases in BDNF expression in animal models.
What the research has reported
Semax has a substantial research history, with over 200 PubMed-indexed citations dating back to the 1990s, spanning BDNF/NGF signalling, neuroprotection in stroke models, and neurotransmitter modulation. It has been the subject of both preclinical and some clinical research. Researchers note an important limitation: the majority of the evidence base — including the human clinical research — originates from Russian research institutions and journals, with comparatively limited independent international replication and long-term Western trial data.
Regulatory status in Australia
Semax has been a registered prescription medicine in Russia and Ukraine for certain indications, but approval in one country does not constitute approval in another. In Australia, Semax has not been approved by the Therapeutic Goods Administration (TGA), is not listed on the Australian Register of Therapeutic Goods (ARTG), and is not approved for therapeutic use. It is supplied strictly as a research compound.
Important disclaimer
This article is provided for informational and laboratory-research purposes only. Semax is supplied strictly as a research compound, for in-vitro laboratory research use only. It is not for human or animal consumption. Nothing in this article constitutes medical advice, nor a recommendation for use in humans. Always refer to current published literature and applicable regulations.